SG10201510082XA - Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine - Google Patents

Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine

Info

Publication number: SG10201510082XA
Authority: SG; Singapore
Prior art keywords: phenyl; piperidin; isopropoxy; pyrimidine; sulfonyl
Prior art date: 2010-12-17

Application number

SG10201510082XA

Inventor

Lili Feng

Baoqing Gong

Piotr H Karpinski

Liladhar Murlidhar Waykole

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-12-17

Filing date

2011-12-15

Publication date

2016-01-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45464892&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG10201510082X(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-12-15 Application filed by Novartis Ag filed Critical Novartis Ag

2016-01-28 Publication of SG10201510082XA publication Critical patent/SG10201510082XA/en

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

SG10201510082XA 2010-12-17 2011-12-15 Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine SG10201510082XA (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201061424194P	2010-12-17	2010-12-17

Publications (1)

Publication Number	Publication Date
SG10201510082XA true SG10201510082XA (en)	2016-01-28

Family

ID=45464892

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SG2013039342A SG190856A1 (en)	2010-12-17	2011-12-15	Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
SG10201510082XA SG10201510082XA (en)	2010-12-17	2011-12-15	Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
SG2013039342A SG190856A1 (en)	2010-12-17	2011-12-15	Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine

Country Status (35)

Country	Link
US (2)	US9309229B2 (en)
EP (3)	EP2651918B1 (en)
JP (1)	JP5916752B2 (en)
KR (4)	KR20190022903A (en)
CN (7)	CN107056751A (en)
AR (2)	AR084309A1 (en)
AU (1)	AU2011343775B2 (en)
BR (1)	BR112013015000A2 (en)
CA (1)	CA2821102C (en)
CL (1)	CL2013001723A1 (en)
CO (1)	CO6801792A2 (en)
CY (2)	CY1119474T1 (en)
DK (2)	DK2651918T3 (en)
EC (1)	ECSP13012770A (en)
ES (3)	ES2905973T3 (en)
GT (1)	GT201300153A (en)
HR (2)	HRP20171477T1 (en)
HU (1)	HUE041845T2 (en)
IL (1)	IL226474A (en)
LT (2)	LT3121171T (en)
MA (1)	MA34771B1 (en)
MX (1)	MX338210B (en)
MY (2)	MY164810A (en)
NZ (1)	NZ610713A (en)
PE (1)	PE20140698A1 (en)
PL (2)	PL2651918T3 (en)
PT (2)	PT2651918T (en)
RS (1)	RS57771B1 (en)
RU (2)	RU2599785C3 (en)
SG (2)	SG190856A1 (en)
SI (2)	SI2651918T1 (en)
TN (1)	TN2013000216A1 (en)
TW (2)	TWI576344B (en)
WO (1)	WO2012082972A1 (en)
ZA (1)	ZA201303599B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN107056751A (en)	2010-12-17	2017-08-18	诺华股份有限公司	A kind of crystal form of ALK inhibitor
CA2890006C (en)	2012-11-06	2021-11-23	Shanghai Fochon Pharmaceutical Co Ltd	Alk kinase inhibitors
KR101656382B1 (en) *	2014-02-28	2016-09-09	한국화학연구원	pyrimidine-2,4-diamine derivatives and pharmaceutical composition for anti cancer containing the same as an active ingredient
CN105272921A (en) *	2014-06-09	2016-01-27	江苏奥赛康药业股份有限公司	Method for preparing Ceritinib and intermediate compound of Ceritinib
CN105294649B (en) *	2014-07-30	2019-05-14	江苏奥赛康药业股份有限公司	A kind of Ceritinib compound and its pharmaceutical composition
CN105294650A (en) *	2014-08-01	2016-02-03	江苏奥赛康药业股份有限公司	Ceritinib compound and pharmaceutical composition thereof
CN111825717A (en)	2014-10-21	2020-10-27	阿瑞雅德制药公司	Crystalline forms of 5-chloro-N4- [2- (dimethylphosphoryl) phenyl ] -N2- { 2-methoxy-4- [4- (4-methylpiperazin-1-yl) piperidin-1-yl ] phenyl } pyrimidine-2, 4-diamine
WO2016081538A1 (en)	2014-11-18	2016-05-26	Teva Pharmaceuticals International Gmbh	Solid state forms of ceritinib and salts thereof
CN105601614A (en) *	2014-11-21	2016-05-25	奥浦顿（上海）医药科技有限公司	Ceritinib crystal form and preparation method thereof
WO2016082795A1 (en) *	2014-11-28	2016-06-02	苏州晶云药物科技有限公司	Crystal form i of ceritinib and preparation method therefor
CN105622577A (en) *	2014-11-29	2016-06-01	江苏先声药业有限公司	Novel crystallographic form of ceritinib and preparation method of novel crystallographic form
WO2016108123A2 (en) *	2014-12-17	2016-07-07	Dr. Reddy’S Laboratories Limited	Pure amorphous and amorphous solid dispersion of ceritinib
WO2016098042A1 (en) *	2014-12-19	2016-06-23	Novartis Ag	Use of ceritinib (ldk-378) in the treatment of fes or fer mediated disorders, in particular proliferative disorders
WO2016098070A1 (en)	2014-12-19	2016-06-23	Novartis Ag	Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
WO2017016529A1 (en)	2015-07-28	2017-02-02	Zentiva, K.S.	Solid forms of ceritinib free base
CN105061397B (en) *	2015-08-07	2018-01-02	武汉英普瑞医药科技有限公司	A kind of c-type crystal formation of Ceritinib and preparation method and application
CN106699743B (en)	2015-11-05	2020-06-12	湖北生物医药产业技术研究院有限公司	Pyrimidine derivative and application thereof
WO2017152858A1 (en) *	2016-03-11	2017-09-14	苏州晶云药物科技有限公司	Crystal form of ceritinib and preparation method thereof
WO2017158619A1 (en)	2016-03-15	2017-09-21	Natco Pharma Limited	A modified process for the preparation of ceritinib and amorphous form of ceritinib
JP2019196359A (en) *	2019-06-17	2019-11-14	ノバルティスアーゲー	Chemical process for preparing pyrimidine derivatives and intermediates thereof
GB201915618D0 (en)	2019-10-28	2019-12-11	Univ Oslo	ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases
JP2023510628A (en) *	2020-01-17	2023-03-14	山東軒竹医薬科技有限公司	Crystal Forms of Polycyclic Inhibitors of Anaplastic Lymphoma Kinase

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0206215D0 (en)	2002-03-15	2002-05-01	Novartis Ag	Organic compounds
CA2533320A1 (en) *	2003-08-15	2006-02-24	Novartis Ag	2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
GB0419161D0 (en) *	2004-08-27	2004-09-29	Novartis Ag	Organic compounds
EA019941B1 (en) *	2006-12-08	2014-07-30	АйАрЭм ЭлЭлСи	Compounds and compositions as protein kinase inhibitors
CN103641833A (en) *	2006-12-08	2014-03-19	Irm责任有限公司	Compounds and compositions as protein kinase inhibitors
MX2010002336A (en) *	2007-08-28	2010-03-25	Irm Llc	Compounds and compositions as kinase inhibitors.
WO2009032694A1 (en) *	2007-08-28	2009-03-12	Dana Farber Cancer Institute	Amino substituted pyrimidine, pyrollopyridine and pyrazolopyrimidine derivatives useful as kinase inhibitors and in treating proliferative disorders and diseases associated with angiogenesis
BRPI0911228A2 (en) *	2008-04-07	2017-05-30	Irm Llc	compounds and compositions as protein kinase inhibitors
KR101956261B1 (en) *	2008-05-21	2019-03-08	어리어드 파마슈티칼스, 인코포레이티드	Phosphorous derivatives as kinase inhibitors
EP2440534A2 (en) *	2009-06-10	2012-04-18	Cellzome Limited	Pyrimidine derivatives as zap-70 inhibitors
TWI481607B (en)	2009-12-17	2015-04-21	Lundbeck & Co As H	2-arylimidazole derivatives as pde10a enzyme inhibitors
CN107056751A (en) *	2010-12-17	2017-08-18	诺华股份有限公司	A kind of crystal form of ALK inhibitor
BR112013015166A2 (en)	2010-12-17	2016-07-12	Du Pont	compound selected from formula 1, fungicidal composition and method for controlling plant diseases
PL2651902T3 (en)	2010-12-17	2018-04-30	Reata Pharmaceuticals, Inc.	Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
CN105294650A (en)	2014-08-01	2016-02-03	江苏奥赛康药业股份有限公司	Ceritinib compound and pharmaceutical composition thereof
WO2016081538A1 (en)	2014-11-18	2016-05-26	Teva Pharmaceuticals International Gmbh	Solid state forms of ceritinib and salts thereof
CN107107792B (en)	2014-11-21	2020-05-19	Tk控股公司	Airbag module
CN105622577A (en)	2014-11-29	2016-06-01	江苏先声药业有限公司	Novel crystallographic form of ceritinib and preparation method of novel crystallographic form
CN107249632A (en)	2014-12-04	2017-10-13	百时美施贵宝公司	Combination for the anti-CS1 and the anti-antibody of PD 1 for the treatment of cancer (myeloma)
WO2016098070A1 (en)	2014-12-19	2016-06-23	Novartis Ag	Crystalline form of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
WO2017016529A1 (en)	2015-07-28	2017-02-02	Zentiva, K.S.	Solid forms of ceritinib free base
CN105061397B (en)	2015-08-07	2018-01-02	武汉英普瑞医药科技有限公司	A kind of c-type crystal formation of Ceritinib and preparation method and application

2011
- 2011-12-15 CN CN201710063793.5A patent/CN107056751A/en active Pending
- 2011-12-15 KR KR1020197005138A patent/KR20190022903A/en active Search and Examination
- 2011-12-15 PE PE2013001425A patent/PE20140698A1/en not_active Application Discontinuation
- 2011-12-15 PT PT118060797T patent/PT2651918T/en unknown
- 2011-12-15 SG SG2013039342A patent/SG190856A1/en unknown
- 2011-12-15 CN CN201710063792.0A patent/CN106831716A/en active Pending
- 2011-12-15 LT LTEP16167355.3T patent/LT3121171T/en unknown
- 2011-12-15 KR KR1020137018605A patent/KR20130130022A/en not_active Application Discontinuation
- 2011-12-15 DK DK11806079.7T patent/DK2651918T3/en active
- 2011-12-15 DK DK16167355.3T patent/DK3121171T3/en active
- 2011-12-15 ES ES18186197T patent/ES2905973T3/en active Active
- 2011-12-15 EP EP11806079.7A patent/EP2651918B1/en not_active Revoked
- 2011-12-15 CN CN201410457562.9A patent/CN104262324A/en active Pending
- 2011-12-15 ES ES16167355T patent/ES2696526T3/en active Active
- 2011-12-15 RS RS20181240A patent/RS57771B1/en unknown
- 2011-12-15 MX MX2013006952A patent/MX338210B/en active IP Right Grant
- 2011-12-15 AU AU2011343775A patent/AU2011343775B2/en active Active
- 2011-12-15 CN CN201610217386.0A patent/CN106008462A/en active Pending
- 2011-12-15 KR KR1020187007996A patent/KR20180032680A/en not_active Application Discontinuation
- 2011-12-15 KR KR1020207009828A patent/KR102325775B1/en active IP Right Grant
- 2011-12-15 US US13/993,217 patent/US9309229B2/en active Active
- 2011-12-15 CA CA2821102A patent/CA2821102C/en active Active
- 2011-12-15 PL PL11806079T patent/PL2651918T3/en unknown
- 2011-12-15 CN CN202210792464.5A patent/CN114989139A/en active Pending
- 2011-12-15 ES ES11806079.7T patent/ES2643016T3/en active Active
- 2011-12-15 SG SG10201510082XA patent/SG10201510082XA/en unknown
- 2011-12-15 AR ARP110104703A patent/AR084309A1/en not_active Application Discontinuation
- 2011-12-15 EP EP18186197.2A patent/EP3453708B8/en active Active
- 2011-12-15 PL PL16167355T patent/PL3121171T3/en unknown
- 2011-12-15 EP EP16167355.3A patent/EP3121171B1/en active Active
- 2011-12-15 RU RU2013132947A patent/RU2599785C3/en active Protection Beyond IP Right Term
- 2011-12-15 MY MYPI2013001848A patent/MY164810A/en unknown
- 2011-12-15 CN CN202011050061.0A patent/CN112125884A/en active Pending
- 2011-12-15 MY MYPI2016001551A patent/MY177742A/en unknown
- 2011-12-15 CN CN201180060435XA patent/CN103282359A/en active Pending
- 2011-12-15 JP JP2013544762A patent/JP5916752B2/en active Active
- 2011-12-15 PT PT16167355T patent/PT3121171T/en unknown
- 2011-12-15 LT LTEP11806079.7T patent/LT2651918T/en unknown
- 2011-12-15 HU HUE16167355A patent/HUE041845T2/en unknown
- 2011-12-15 WO PCT/US2011/065030 patent/WO2012082972A1/en active Application Filing
- 2011-12-15 BR BR112013015000A patent/BR112013015000A2/en not_active Application Discontinuation
- 2011-12-15 RU RU2016136823A patent/RU2746159C2/en active
- 2011-12-15 NZ NZ610713A patent/NZ610713A/en not_active IP Right Cessation
- 2011-12-15 SI SI201131289T patent/SI2651918T1/en unknown
- 2011-12-15 SI SI201131583T patent/SI3121171T1/en unknown
- 2011-12-16 TW TW105112710A patent/TWI576344B/en active
- 2011-12-16 TW TW100146987A patent/TWI576343B/en active
2013
- 2013-05-17 TN TNP2013000216A patent/TN2013000216A1/en unknown
- 2013-05-17 ZA ZA2013/03599A patent/ZA201303599B/en unknown
- 2013-05-20 IL IL226474A patent/IL226474A/en active IP Right Grant
- 2013-06-14 CL CL2013001723A patent/CL2013001723A1/en unknown
- 2013-06-17 GT GT201300153A patent/GT201300153A/en unknown
- 2013-06-28 MA MA36066A patent/MA34771B1/en unknown
- 2013-07-04 CO CO13158446A patent/CO6801792A2/en not_active Application Discontinuation
- 2013-07-16 EC ECSP13012770 patent/ECSP13012770A/en unknown
2016
- 2016-03-02 US US15/058,489 patent/US20160175305A1/en not_active Abandoned
2017
- 2017-10-03 HR HRP20171477TT patent/HRP20171477T1/en unknown
- 2017-10-11 CY CY20171101064T patent/CY1119474T1/en unknown
2018
- 2018-10-22 HR HRP20181737TT patent/HRP20181737T1/en unknown
- 2018-11-09 CY CY181101192T patent/CY1121017T1/en unknown
2021
- 2021-03-19 AR ARP210100698A patent/AR122395A2/en unknown

Also Published As

Publication number	Publication date
CN114989139A (en)	2022-09-02
IL226474A0 (en)	2013-07-31
CN107056751A (en)	2017-08-18
MA34771B1 (en)	2013-12-03
NZ610713A (en)	2014-10-31
HUE041845T2 (en)	2019-05-28
KR20130130022A (en)	2013-11-29
RS57771B1 (en)	2018-12-31
CA2821102C (en)	2019-06-11
TWI576343B (en)	2017-04-01
SG190856A1 (en)	2013-07-31
RU2016136823A (en)	2018-12-11
EP3121171A1 (en)	2017-01-25
KR20180032680A (en)	2018-03-30
US20160175305A1 (en)	2016-06-23
PL3121171T3 (en)	2019-01-31
CA2821102A1 (en)	2012-06-21
MY177742A (en)	2020-09-23
LT2651918T (en)	2017-10-10
CL2013001723A1 (en)	2013-12-27
CN106008462A (en)	2016-10-12
CN103282359A (en)	2013-09-04
SI2651918T1 (en)	2017-10-30
CN104262324A (en)	2015-01-07
EP3121171B1 (en)	2018-08-15
CO6801792A2 (en)	2013-11-29
PT2651918T (en)	2017-10-17
MX2013006952A (en)	2013-07-15
DK3121171T3 (en)	2018-12-10
RU2599785C3 (en)	2019-04-24
PL2651918T3 (en)	2017-12-29
HRP20171477T1 (en)	2017-11-17
BR112013015000A2 (en)	2016-08-09
DK2651918T3 (en)	2017-10-23
CY1119474T1 (en)	2018-04-04
MX338210B (en)	2016-04-07
PE20140698A1 (en)	2014-06-11
TW201307299A (en)	2013-02-16
AU2011343775A1 (en)	2013-07-18
LT3121171T (en)	2018-11-12
TWI576344B (en)	2017-04-01
RU2013132947A (en)	2015-01-27
US9309229B2 (en)	2016-04-12
PT3121171T (en)	2018-11-27
ES2696526T3 (en)	2019-01-16
ES2643016T3 (en)	2017-11-21
RU2599785C2 (en)	2016-10-20
EP3453708A1 (en)	2019-03-13
EP3453708B8 (en)	2022-03-16
HRP20181737T1 (en)	2018-12-28
GT201300153A (en)	2014-06-09
CN106831716A (en)	2017-06-13
TN2013000216A1 (en)	2014-11-10
AR122395A2 (en)	2022-09-07
KR102325775B1 (en)	2021-11-12
ECSP13012770A (en)	2013-10-31
ZA201303599B (en)	2014-02-26
AR084309A1 (en)	2013-05-08
US20130274279A1 (en)	2013-10-17
EP3453708B1 (en)	2021-10-27
RU2746159C2 (en)	2021-04-08
JP2013545812A (en)	2013-12-26
JP5916752B2 (en)	2016-05-11
AU2011343775B2 (en)	2015-12-03
RU2016136823A3 (en)	2020-02-06
KR20190022903A (en)	2019-03-06
EP2651918A1 (en)	2013-10-23
IL226474A (en)	2016-03-31
ES2905973T3 (en)	2022-04-12
CY1121017T1 (en)	2019-12-11
WO2012082972A1 (en)	2012-06-21
MY164810A (en)	2018-01-30
CN112125884A (en)	2020-12-25
EP2651918B1 (en)	2017-07-12
TW201629021A (en)	2016-08-16
SI3121171T1 (en)	2018-11-30
KR20200039021A (en)	2020-04-14

Publication	Publication Date	Title
IL226474A0 (en)	2013-07-31	Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
IL242278A0 (en)	2015-11-30	Substituted n-(4-fluoro-2-methoxy-5-nitrophenyl)pyrimidin-2-amine compounds, and salts thereof
GB201001075D0 (en)	2010-03-10	Crystalline forms
ZA201209029B (en)	2014-02-26	Novel pyrimidine derivatives
GB201012105D0 (en)	2010-09-01	Novel pyrimidine compounds
PT2785181T (en)	2016-10-25	2-(substituted-phenyl)-cyclopentane-1,3-dione compounds, and derivatives thereof
EP2445346A4 (en)	2012-12-05	Oxo-heterocycle fused pyrimidine compounds, compositions and methods of use
IL215119A0 (en)	2011-12-29	Substitted fused pyrimidine compounds
SI2545048T1 (en)	2014-12-31	Raltegravir salts and crystalline forms thereof
HK1210403A1 (en)	2016-04-22	Condensing implant
EP2560655A4 (en)	2013-09-04	Substituted pyrimidines
PL2578595T3 (en)	2017-10-31	Crystalline levoisovalerylspiramycin i
EP2758058A4 (en)	2015-08-19	Substituted pyrimidines
EP2758059A4 (en)	2015-07-22	Substituted pyrimidines
EP2735567A4 (en)	2015-03-18	Heterocyclic substituted pyrimidine compound
GB201019013D0 (en)	2010-12-22	Bone formation
ZA201106695B (en)	2013-02-27	Substituted fused pyrimidine compounds
AU2011904399A0 (en)	2011-11-10	Intramedullary prosthesis